Literature DB >> 24422631

The von hippel-lindau protein suppresses androgen receptor activity.

Jing Wang1, Wei Zhang, Wei Ji, Xing Liu, Gang Ouyang, Wuhan Xiao.   

Abstract

The androgen receptor (AR) plays a pivotal role in prostate homeostasis and prostate cancer development. To understand the mechanism underlying the regulation of the AR holds a promise for developing novel therapeutic approaches for prostate cancer. Here, we show that the Von Hippel-Lindau gene product, pVHL, physically interacts with AR and inhibits AR transcription activity but does not induce AR turnover. Moreover, pVHL also suppresses androgen-induced cell proliferation, implicating a physiological role of pVHL in androgen-induced signaling pathway. In addition, we provide evidence to show that pVHL actually enhanced AR de-ubiquitination instead of inducing AR ubiquitination, uncovering a noncanonical role of pVHL in the ubiquitin proteasome pathway. Our data reveal a novel function of pVHL in the regulation of AR transcription activity, which may expand the scope of pVHL in tumor suppression and provide mechanistic insight into prostate cancer initiation and progression.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24422631      PMCID: PMC5427956          DOI: 10.1210/me.2013-1258

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  37 in total

1.  Regulation of cellular levels of Sprouty2 protein by prolyl hydroxylase domain and von Hippel-Lindau proteins.

Authors:  Kimberly Anderson; Kyle A Nordquist; Xianlong Gao; Kristin C Hicks; Bo Zhai; Steven P Gygi; Tarun B Patel
Journal:  J Biol Chem       Date:  2011-10-17       Impact factor: 5.157

2.  Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1.

Authors:  Changmeng Cai; Housheng Hansen He; Sen Chen; Ilsa Coleman; Hongyun Wang; Zi Fang; Shaoyong Chen; Peter S Nelson; X Shirley Liu; Myles Brown; Steven P Balk
Journal:  Cancer Cell       Date:  2011-10-18       Impact factor: 31.743

3.  Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein.

Authors:  M E Cockman; N Masson; D R Mole; P Jaakkola; G W Chang; S C Clifford; E R Maher; C W Pugh; P J Ratcliffe; P H Maxwell
Journal:  J Biol Chem       Date:  2000-08-18       Impact factor: 5.157

4.  The von Hippel-Lindau tumor suppressor protein mediates ubiquitination of activated atypical protein kinase C.

Authors:  H Okuda; K Saitoh; S Hirai; K Iwai; Y Takaki; M Baba; N Minato; S Ohno; T Shuin
Journal:  J Biol Chem       Date:  2001-09-26       Impact factor: 5.157

5.  p53 directly suppresses BNIP3 expression to protect against hypoxia-induced cell death.

Authors:  Xi Feng; Xing Liu; Wei Zhang; Wuhan Xiao
Journal:  EMBO J       Date:  2011-07-26       Impact factor: 11.598

6.  p53 stabilization and transactivation by a von Hippel-Lindau protein.

Authors:  Jae-Seok Roe; Hyungsoo Kim; Soon-Min Lee; Sung-Tae Kim; Eun-Jung Cho; Hong-Duk Youn
Journal:  Mol Cell       Date:  2006-05-05       Impact factor: 17.970

Review 7.  The von hippel-lindau tumor suppressor protein: an update.

Authors:  William G Kaelin
Journal:  Methods Enzymol       Date:  2007       Impact factor: 1.600

8.  De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling.

Authors:  Ingrid E Wertz; Karen M O'Rourke; Honglin Zhou; Michael Eby; L Aravind; Somasekar Seshagiri; Ping Wu; Christian Wiesmann; Rohan Baker; David L Boone; Averil Ma; Eugene V Koonin; Vishva M Dixit
Journal:  Nature       Date:  2004-07-18       Impact factor: 49.962

Review 9.  The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer.

Authors:  William G Kaelin
Journal:  Nat Rev Cancer       Date:  2008-10-16       Impact factor: 60.716

10.  Molecular determinants of resistance to antiandrogen therapy.

Authors:  Charlie D Chen; Derek S Welsbie; Chris Tran; Sung Hee Baek; Randy Chen; Robert Vessella; Michael G Rosenfeld; Charles L Sawyers
Journal:  Nat Med       Date:  2003-12-21       Impact factor: 53.440

View more
  10 in total

1.  FBXO32 Targets c-Myc for Proteasomal Degradation and Inhibits c-Myc Activity.

Authors:  Zhichao Mei; Dawei Zhang; Bo Hu; Jing Wang; Xian Shen; Wuhan Xiao
Journal:  J Biol Chem       Date:  2015-05-05       Impact factor: 5.157

2.  Forkhead Transcription Factor 3a (FOXO3a) Modulates Hypoxia Signaling via Up-regulation of the von Hippel-Lindau Gene (VHL).

Authors:  Xing Liu; Xiaolian Cai; Bo Hu; Zhichao Mei; Dawei Zhang; Gang Ouyang; Jing Wang; Wei Zhang; Wuhan Xiao
Journal:  J Biol Chem       Date:  2016-10-24       Impact factor: 5.157

3.  Differential regulation of LncRNA-SARCC suppresses VHL-mutant RCC cell proliferation yet promotes VHL-normal RCC cell proliferation via modulating androgen receptor/HIF-2α/C-MYC axis under hypoxia.

Authors:  W Zhai; Y Sun; M Jiang; M Wang; T A Gasiewicz; J Zheng; C Chang
Journal:  Oncogene       Date:  2016-03-14       Impact factor: 9.867

4.  TET is targeted for proteasomal degradation by the PHD-pVHL pathway to reduce DNA hydroxymethylation.

Authors:  Sijia Fan; Jing Wang; Guangqing Yu; Fangjing Rong; Dawei Zhang; Chenxi Xu; Juan Du; Zhi Li; Gang Ouyang; Wuhan Xiao
Journal:  J Biol Chem       Date:  2020-09-22       Impact factor: 5.157

Review 5.  Post-Translational Modifications That Drive Prostate Cancer Progression.

Authors:  Ivana Samaržija
Journal:  Biomolecules       Date:  2021-02-09

6.  Tet1 facilitates hypoxia tolerance by stabilizing the HIF-α proteins independent of its methylcytosine dioxygenase activity.

Authors:  Jing Wang; Dawei Zhang; Juan Du; Chi Zhou; Zhi Li; Xing Liu; Gang Ouyang; Wuhan Xiao
Journal:  Nucleic Acids Res       Date:  2017-12-15       Impact factor: 16.971

7.  Beluga whale pVHL enhances HIF-2α activity via inducing HIF-2α proteasomal degradation under hypoxia.

Authors:  Jianling Bi; Bo Hu; Jing Wang; Xing Liu; Jinsong Zheng; Ding Wang; Wuhan Xiao
Journal:  Oncotarget       Date:  2017-06-27

8.  A Novel Flavonoid Composition Targets Androgen Receptor Signaling and Inhibits Prostate Cancer Growth in Preclinical Models.

Authors:  Kenza Mamouni; Shumin Zhang; Xin Li; Yanhua Chen; Yang Yang; Jaeah Kim; Michael G Bartlett; Ilsa M Coleman; Peter S Nelson; Omer Kucuk; Daqing Wu
Journal:  Neoplasia       Date:  2018-07-04       Impact factor: 5.715

9.  The pVHL neglected functions, a tale of hypoxia-dependent and -independent regulations in cancer.

Authors:  Giovanni Minervini; Maria Pennuto; Silvio C E Tosatto
Journal:  Open Biol       Date:  2020-07-01       Impact factor: 6.411

10.  ELL targets c-Myc for proteasomal degradation and suppresses tumour growth.

Authors:  Yu Chen; Chi Zhou; Wei Ji; Zhichao Mei; Bo Hu; Wei Zhang; Dawei Zhang; Jing Wang; Xing Liu; Gang Ouyang; Jiangang Zhou; Wuhan Xiao
Journal:  Nat Commun       Date:  2016-03-24       Impact factor: 14.919

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.